"Building A Better Biotech: The Story of Regeneron"
George Yancopoulos, MD, PhD
President and Chief Scientific Officer
Thursday, February 1, 2018
Clyde and Helen Wu Auditorium,
Roy and Diana Vagelos Education Center
104 Haven Avenue
Recption to follow
George D. Yancopoulos, M.D., Ph.D., joined Regeneron in 1989 as its Scientific Founder and is currently the President and Chief Scientific Officer . He received his M.D. and Ph.D. degrees in Biochemistry and Molecular Biophysics from Columbia University. In the 1990s, Dr. Yancopoulos was the 11th most highly cited scientist in the world, and in 2004 he was elected to both the National Academy of Sciences and the American Academy of Arts & Sciences. Dr. Yancopoulos, together with key members of his team, is principal inventor and developer of Regeneron's four FDA-approved drugs: PRALUENT® (alirocumab) Injection, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection as well as of Regeneron's foundational technologies for target and drug development, such as its proprietary TRAP technology, VelociGene® and VelocImmune®. These technologies have produced Regeneron's robust pipeline of fully human antibodies targeting cholesterol-lowering efforts, rheumatoid arthritis, atopic dermatitis, asthma, pain, cancer, and infectious diseases. In 2014, Dr. Yancopoulos and his team launched the Regeneron Genetics Center, a major new initiative in human genetic research that has already sequenced exomes from more than 120,000 people.